Vaccination with three tandem repeats of M2 extracellular domain fused to Leismania major HSP70 protects mice against influenza A virus challenge.

[1]  D. Putnam,et al.  Recombinant M2e outer membrane vesicle vaccines protect against lethal influenza A challenge in BALB/c mice. , 2016, Vaccine.

[2]  P. Thomas,et al.  Balancing Immune Protection and Immune Pathology by CD8+ T-Cell Responses to Influenza Infection , 2016, Front. Immunol..

[3]  N. Ravin,et al.  High immunogenicity of plant-produced candidate influenza vaccine based on the M2e peptide fused to flagellin , 2016, Bioengineered.

[4]  J. Treanor.  Prospects for broadly protective influenza vaccines. , 2015, Vaccine.

[5]  A. Latifi,et al.  A truncated C-terminal fragment of Mycobacterium tuberculosis HSP70 enhances cell-mediated immune response and longevity of the total IgG to influenza A virus M2e protein in mice. , 2015, Antiviral research.

[6]  Carlo Montemagno,et al.  Microneedle patch delivery to the skin of virus-like particles containing heterologous M2e extracellular domains of influenza virus induces broad heterosubtypic cross-protection. , 2015, Journal of controlled release : official journal of the Controlled Release Society.

[7]  E. Fodor,et al.  Conserved and host-specific features of influenza virion architecture , 2014, Nature Communications.

[8]  K. Subbarao,et al.  The prospects and challenges of universal vaccines for influenza. , 2013, Trends in microbiology.

[9]  Lorne A. Babiuk,et al.  Mechanisms of Action of Adjuvants , 2013, Front. Immunol..

[10]  N. Mattion,et al.  Tandem repeats of the extracellular domain of Matrix 2 influenza protein exposed in Brucella lumazine synthase decameric carrier molecule induce protection in mice. , 2013, Vaccine.

[11]  Xintao Zhang,et al.  Vaccination with Different M2e Epitope Densities Confers Partial Protection against H5N1 Influenza A Virus Challenge in Chickens , 2011, Intervirology.

[12]  M. Tebianian,et al.  Role of Mycobacterial Heat Shock Protein 70 (mHSP70) as Genetic Vaccine Adjuvants , 2011 .

[13]  M. Tebianian,et al.  Influenza A viruses: why focusing on M2e-based universal vaccines , 2011, Virus Genes.

[14]  Shibo Jiang,et al.  Research and development of universal influenza vaccines. , 2010, Microbes and infection.

[15]  C. Kallenberg,et al.  Cell-mediated immune responses to influenza vaccination in Wegener's granulomatosis , 2009, Annals of the rheumatic diseases.

[16]  W. Fiers,et al.  Universal influenza A M2e-HBc vaccine protects against disease even in the presence of pre-existing anti-HBc antibodies. , 2008, Vaccine.

[17]  Pang-Chui Shaw,et al.  Structure of the influenza virus A H5N1 nucleoprotein: implications for RNA binding, oligomerization, and vaccine design , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[18]  H. Hammad,et al.  Cutting Edge: Alum Adjuvant Stimulates Inflammatory Dendritic Cells through Activation of the NALP3 Inflammasome , 2008, The Journal of Immunology.

[19]  G. Boivin,et al.  Development of a universal influenza A vaccine based on the M2e peptide fused to the papaya mosaic virus (PapMV) vaccine platform. , 2008, Vaccine.

[20]  R. K. Evans,et al.  Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin. , 2008, Vaccine.

[21]  Ying-hua Chen,et al.  Characterization of immunity induced by M2e of influenza virus. , 2007, Vaccine.

[22]  S. Rafati,et al.  Leishmania major heat shock protein 70 (HSP70) is not protective in murine models of cutaneous leishmaniasis and stimulates strong humoral responses in cutaneous and visceral leishmaniasis patients. , 2007, Vaccine.

[23]  T. Tumpey,et al.  Matrix Protein 2 Vaccination and Protection against Influenza Viruses, Including Subtype H5N1 , 2007, Emerging infectious diseases.

[24]  B. Beutler,et al.  Adjuvant-Enhanced Antibody Responses in the Absence of Toll-Like Receptor Signaling , 2006, Science.

[25]  E. Repasky,et al.  Heat shock proteins as vaccine adjuvants in infections and cancer. , 2006, Drug discovery today.

[26]  G. Multhoff.  Heat shock proteins in immunity. , 2006, Handbook of experimental pharmacology.

[27]  P. Marrack,et al.  Promotion of B Cell Immune Responses via an Alum-Induced Myeloid Cell Population , 2004, Science.

[28]  R. Medzhitov,et al.  Adjuvants of Immunity , 2002, The Journal of experimental medicine.

[29]  G. Tau,et al.  Regulation of IFN-γ Signaling Is Essential for the Cytotoxic Activity of CD8+ T Cells1 , 2001, The Journal of Immunology.

[30]  C. Hunter,et al.  Aluminium hydroxide adjuvant initiates strong antigen-specific Th2 responses in the absence of IL-4- or IL-13-mediated signaling. , 1999, Journal of immunology.

[31]  A. Khoruts,et al.  Inflammatory cytokines enhance the in vivo clonal expansion and differentiation of antigen-activated CD4+ T cells. , 1997, Journal of immunology.

[32]  A. Kendal,et al.  Antibody response to the M2 protein of influenza A virus expressed in insect cells. , 1993, The Journal of general virology.